

Publikationen:

- Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial
Rudolf M. Huber et al.
Journal of Thoracic Oncology Vol. 15 No. 3: 404-415 Published online - 19 November 2019
<https://doi.org/10.1016/j.jtho.2019.11.004>
- Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib
Nobuyuki Yamamoto et al.
Advances in Therapy volume 37, pages759–769(2020) Published: 20 December 2019
<https://doi.org/10.1007/s12325-019-01187-y>
- Respiratory Sinus Arrhythmia Attenuation via Targeted Lung Denervation in Sheep and Humans
Valipour A et al.
Respiration. 2019;98(5):434-439 published: November 2019
<https://doi.org/10.1159/000501623>
- Safety and Adverse Events after Targeted Lung Denervation for Symptomatic Moderate to Severe Chronic Obstructive Pulmonary Disease (AIRFLOW). A Multicenter Randomized Controlled Clinical Trial.
Slebos DJ et al.
Am J Respir Crit Care Med. 2019 Dec 15;200(12):1477-1486.
<https://doi.org/10.1164/rccm.201903-0624OC>